Skip to main navigation Skip to search Skip to main content

Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients

  • M Bakker
  • , JP Droz
  • , AR Hanauske
  • , Jaap Verweij
  • , AT van Oosterom
  • , HJM Groen
  • , MA Pacciarini
  • , L Domenigoni
  • , F van Weissenbruch
  • , E Pianezzola
  • , EGE de Vries

Research output: Contribution to journal › Article › Academic › peer-review

16 Citations (Scopus)
Original languageUndefined/Unknown
Pages (from-to)139-146
Number of pages8
JournalBritish Journal of Cancer
Volume77
Issue number1
Publication statusPublished - 1998

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research programs

  • EMC 04-01-DD-08-01

Cite this